BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 23077235)

  • 1. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
    Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
    Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation.
    Popovic-Todorovic B; Santos-Ribeiro S; Drakopoulos P; De Vos M; Racca A; Mackens S; Thorrez Y; Verheyen G; Tournaye H; Quintero L; Blockeel C
    Hum Reprod; 2019 Oct; 34(10):2027-2035. PubMed ID: 31560740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How far is too far? Does time interval between GnRH antagonist and GnRH agonist trigger in GnRH antagonist cycles matter?
    Hershko Klement A; Orvieto R; Esh Broder E; Frei J; Solnica A; Zandman O; Holzer H; Haas J
    Reprod Biomed Online; 2021 Aug; 43(2):233-238. PubMed ID: 34215488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
    Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
    Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment.
    Abbara A; Hunjan T; Ho VNA; Clarke SA; Comninos AN; Izzi-Engbeaya C; Ho TM; Trew GH; Hramyka A; Kelsey T; Salim R; Humaidan P; Vuong LN; Dhillo WS
    Front Endocrinol (Lausanne); 2020; 11():537205. PubMed ID: 33123084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R
    J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte maturation and corpus luteum function.
    Zelinski-Wooten MB; Lanzendorf SE; Wolf DP; Chandrasekher YA; Stouffer RL
    J Clin Endocrinol Metab; 1991 Sep; 73(3):577-83. PubMed ID: 1908481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes.
    Zilberberg E; Haas J; Dar S; Kedem A; Machtinger R; Orvieto R
    Gynecol Endocrinol; 2015 Feb; 31(2):145-7. PubMed ID: 25385007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist.
    Kummer N; Benadiva C; Feinn R; Mann J; Nulsen J; Engmann L
    Fertil Steril; 2011 Jul; 96(1):63-8. PubMed ID: 21565337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual luteolysis pattern after GnRH-agonist trigger for final oocyte maturation.
    Lawrenz B; Garrido N; Samir S; Ruiz F; Melado L; Fatemi HM
    PLoS One; 2017; 12(5):e0176600. PubMed ID: 28459828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-Detection of the LH Surge in Urine After GnRH Agonist Trigger in IVF-How to Minimize Failure to Retrieve Oocytes.
    Cozzolino M; Matey S; Alvarez A; Toribio M; López V; Perona M; Henzenn E; Piró M; Humaidan P; Garcia-Velasco JA
    Front Endocrinol (Lausanne); 2020; 11():221. PubMed ID: 32390942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 45.